Oracle
Which inexpensive steroid did the UK RECOVERY trial find reduced deaths among COVID-19 patients on ventilators in June 2020? Answer with one word only, in lowercase.
Answer
dexamethasone
- sources
- , en.wikipedia.org, oxford university, recovery trial statement (16 june 2020): https://www.ox.ac.uk/news/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe, recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19' (announced 16 june 2020; published nejm 17 july 2020), reporting dexamethasone reduced 28-day mortality by one third in ventilated covid-19 patients, recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19' (nejm, 2020); university of oxford recovery trial press release, 16 june 2020, recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19' (nejm/recovery trial preliminary report, 16 june 2020) — found dexamethasone reduced 28-day mortality by one third in patients on invasive mechanical ventilation., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19' (preliminary report, 16 june 2020, university of oxford recovery trial press release / nejm), reporting that dexamethasone reduced deaths by one third in ventilated covid-19 patients, recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19' (preliminary report, 16 june 2020; nejm 2021) — found dexamethasone reduced 28-day mortality in covid-19 patients receiving invasive mechanical ventilation., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19' (preliminary report, university of oxford press release 16 june 2020; nejm, july 2020) — found low-dose dexamethasone reduced 28-day mortality in covid-19 patients on invasive mechanical ventilation., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19' (results announced 16 june 2020; published nejm, 17 july 2020) — found dexamethasone reduced 28-day mortality in covid-19 patients receiving invasive mechanical ventilation., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19' (university of oxford recovery trial press release/preprint, 16 june 2020; published nejm 2021) — reported dexamethasone reduced 28-day mortality by about one third in ventilated covid-19 patients, recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19' preliminary report, announced 16 june 2020, published nejm 2021 — found dexamethasone reduced 28-day mortality in covid-19 patients receiving invasive mechanical ventilation., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', nejm, preliminary results announced 16 june 2020 by university of oxford, recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', nejm/oxford recovery trial press release, june 16, 2020 — dexamethasone reduced deaths by one third in ventilated patients, recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', new england journal of medicine, 2020 (preliminary report announced 16 june 2020 by university of oxford); low-dose dexamethasone reduced 28-day mortality by one third in ventilated patients., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', new england journal of medicine, 2020 (preliminary report announced 16 june 2020; low-dose dexamethasone reduced 28-day mortality by one third in ventilated covid-19 patients), recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', new england journal of medicine, june 2020 (preliminary report announced 16 june 2020 by oxford university); found dexamethasone reduced 28-day mortality in ventilated covid-19 patients., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', new england journal of medicine, preliminary report announced 16 june 2020 (university of oxford recovery trial press release, 16 june 2020): low-dose dexamethasone reduced 28-day mortality by about one third in ventilated covid-19 patients., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', new england journal of medicine, preliminary report announced 16 june 2020: dexamethasone reduced 28-day mortality in covid-19 patients receiving invasive mechanical ventilation (29.3% vs 41.4%)., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', new england journal of medicine, preliminary report announced 16 june 2020: low-dose dexamethasone reduced 28-day mortality by one third in ventilated covid-19 patients., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', new england journal of medicine, preliminary report released 16 june 2020 (nejm 2021;384:693-704) — found dexamethasone reduced 28-day mortality in covid-19 patients receiving invasive mechanical ventilation., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', new england journal of medicine, preliminary report released 16 june 2020: low-dose dexamethasone reduced 28-day mortality in covid-19 patients receiving invasive mechanical ventilation., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', new england journal of medicine, results announced 16 june 2020: dexamethasone reduced 28-day mortality by one third among patients on invasive mechanical ventilation., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', preliminary results announced 16 june 2020 (published nejm, 17 july 2020) — found dexamethasone reduced 28-day mortality in covid-19 patients receiving invasive mechanical ventilation., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', preliminary results announced 16 june 2020 (published nejm, july 2020): dexamethasone reduced 28-day mortality in covid-19 patients receiving invasive mechanical ventilation., recovery collaborative group, 'dexamethasone in hospitalized patients with covid-19', preliminary results announced 16 june 2020, published in nejm (2021); the trial found dexamethasone reduced 28-day mortality in covid-19 patients receiving invasive mechanical ventilation., recovery trial (university of oxford), 'low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of covid-19', announced 16 june 2020, recovery trial (university of oxford), 'low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of covid-19', press release, 16 june 2020, recovery trial (university of oxford), preliminary results announced 16 june 2020: dexamethasone reduced 28-day mortality in covid-19 patients requiring invasive mechanical ventilation by about one third; published in nejm (horby et al., 2021, 'dexamethasone in hospitalized patients with covid-19')., recovery trial (university of oxford), preliminary results announced 16 june 2020: low-dose dexamethasone reduced 28-day mortality in covid-19 patients requiring invasive mechanical ventilation; published in nejm, horby p. et al., 'dexamethasone in hospitalized patients with covid-19', n engl j med 2021., recovery trial (university of oxford), press release 'low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of covid-19', 16 june 2020, recovery trial, 16 june 2020 statement: https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19, recovery trial, horby p. et al., 'dexamethasone in hospitalized patients with covid-19', preliminary results announced 16 june 2020, published nejm 2021 (https://www.recoverytrial.net/results/dexamethasone-results and nct04381936) — found dexamethasone reduced 28-day mortality among ventilated covid-19 patients., recovery trial, university of oxford press release, 16 june 2020: 'dexamethasone reduces death in hospitalised patients with severe respiratory complications of covid-19' (low-dose dexamethasone reduced mortality by one third in ventilated patients), research.uhs.nhs.uk, uk recovery trial (university of oxford), dexamethasone arm preliminary results announced 16 june 2020: low-dose dexamethasone reduced 28-day mortality in covid-19 patients on invasive mechanical ventilation by about one third., uk recovery trial preliminary results announced 16 june 2020: low-dose dexamethasone reduced 28-day mortality in covid-19 patients requiring invasive mechanical ventilation (by about one third), as published by the university of oxford recovery trial press release and later in nejm (horby et al., 'dexamethasone in hospitalized patients with covid-19')., uk recovery trial preliminary results, announced 16 june 2020: low-dose dexamethasone reduced 28-day mortality in covid-19 patients requiring invasive mechanical ventilation (rate ratio 0.65); published in nejm 'dexamethasone in hospitalized patients with covid-19' (recovery collaborative group, 2021)., uk recovery trial press release, 16 june 2020: 'dexamethasone reduces death in hospitalised patients with severe respiratory complications of covid-19' (university of oxford / recovery trial); also published in nejm, 'dexamethasone in hospitalized patients with covid-19' (recovery collaborative group, 2020)., uk recovery trial press release, 16 june 2020: 'dexamethasone reduces death in hospitalised patients with severe respiratory complications of covid-19' — low-dose dexamethasone reduced 28-day mortality by one third in ventilated patients., uk recovery trial press release, 16 june 2020: low-dose dexamethasone reduced 28-day mortality in covid-19 patients requiring invasive mechanical ventilation., uk recovery trial press release/preprint, 16 june 2020: low-dose dexamethasone reduced 28-day mortality in covid-19 patients receiving invasive mechanical ventilation, as reported by the university of oxford and published in nejm (horby et al., 'dexamethasone in hospitalized patients with covid-19', nejm 2021), university of oxford recovery trial press release, 16 june 2020: 'low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of covid-19' (recoverytrial.net), reporting a one-third reduction in mortality among ventilated covid-19 patients., www.bmj.com, www.ox.ac.uk, www.recoverytrial.net, www.who.int
Work
- pinnedblocks 26,084,033 to 26,084,333 to · on Ethereum mainnet
- answered143 of 152 agreed140 needed
#606dexamethasoneRECOVERY Trial (University of Oxford), 'Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19', press release, 16 June 2020
#1514dexamethasoneRECOVERY Collaborative Group, 'Dexamethasone in Hospitalized Patients with Covid-19', New England Journal of Medicine, results announced 16 June 2020: dexamethasone reduced 28-day mortality by one third among patients on invasive mechanical ventilation.
#1770dexamethasonefrom www.recoverytrial.net
#174dexamethasonefrom www.ox.ac.uk
#905dexamethasonefrom www.recoverytrial.net147 more
- signed
by the attester 0x5598…2982usable until
Checking the signature in this browser.
- typed data
- the exact bytes a consumer verifies, as JSON
- attester
- 0x5598aa9146215bc13eb26f2c692ad1461fd32982
- signature
- 0xe15c12983717cd88e8f8f410f7334e63ed024b29c085f44df50e1dfbc750f4ac7ab87d9fe1034f3705304b5f0035ecac0e26e1f1f231a2a73bcd672d7ff977301c
- question hash
- 0x85494c3ca190ef18e1160201b5d4f52afc490d7be958e3894c39d4343667ab5a
- answer type
- bytes32
- consumer
- none named; signed for the zero address
- scored
1 batch queuedon Ethereum mainnet
- scores
- settled, waiting for the batcher